$Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy$

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.10384-10385
Hauptverfasser:	Yang, Fan, Liu, Rui, Xu, Teng, Zheng, Peihao, Feng, Shaomei, Guo, Yuelu, Ma, Lixia, SHI, Hui, Deng, Biping, Ke, Xiaoyan, Wu, Tong, Hu, Kai
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	10385
container_issue	Supplement 1
container_start_page	10384
container_title	Blood
container_volume	140
creator	Yang, Fan Liu, Rui Xu, Teng Zheng, Peihao Feng, Shaomei Guo, Yuelu Ma, Lixia SHI, Hui Deng, Biping Ke, Xiaoyan Wu, Tong Hu, Kai
description
doi_str_mv	10.1182/blood-2022-164446
format	Article
fullrecord	<record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_164446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712206222X</els_id><sourcerecordid>S000649712206222X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1376-e1d1e295a8fbe2e7fd91d74de35446cb3f37aec22568cc4fd12e2c6ec64b6d33</originalsourceid><addsrcrecordid>eNp90E1OwzAQBWALgUQpHICdL2CwncRpxaoECkiVQG0llpFjj1WjpA62A8qJuCbpzxKxmsXovRl9CF0zesPYhN9WtXOacMo5YSJNU3GCRizjE0Ipp6doRCkVJJ3m7BxdhPBBKUsTno3Qz6qrAnx2sI14BcpttfQ9LmZLssYF1DVeb8DLtsfvMuBV14K3zuPocLGBxsXj0m7xm4x2KAn428YNXoLxUkXn-9sl1LINoPE92Rcu-qbduEZiaSJ4PJe27jxgZ_BsGy0pHtj0j_uX6MzIOsDVcY7Rev64Lp7J4vXppZgtiGJJLggwzYBPMzkxFXDIjZ4ynacakmwwUVViklyC4jwTE6VSoxkHrgQokVZCJ8kYsUOt8i4ED6ZsvW0GkpLRcgdd7qHLHXR5gB4yd4cMDH99WfBlUAOFAm09qFhqZ_9J_wKBFIgj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yang, Fan ; Liu, Rui ; Xu, Teng ; Zheng, Peihao ; Feng, Shaomei ; Guo, Yuelu ; Ma, Lixia ; SHI, Hui ; Deng, Biping ; Ke, Xiaoyan ; Wu, Tong ; Hu, Kai</creator><creatorcontrib>Yang, Fan ; Liu, Rui ; Xu, Teng ; Zheng, Peihao ; Feng, Shaomei ; Guo, Yuelu ; Ma, Lixia ; SHI, Hui ; Deng, Biping ; Ke, Xiaoyan ; Wu, Tong ; Hu, Kai</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-164446</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.10384-10385</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Yang, Fan</creatorcontrib><creatorcontrib>Liu, Rui</creatorcontrib><creatorcontrib>Xu, Teng</creatorcontrib><creatorcontrib>Zheng, Peihao</creatorcontrib><creatorcontrib>Feng, Shaomei</creatorcontrib><creatorcontrib>Guo, Yuelu</creatorcontrib><creatorcontrib>Ma, Lixia</creatorcontrib><creatorcontrib>SHI, Hui</creatorcontrib><creatorcontrib>Deng, Biping</creatorcontrib><creatorcontrib>Ke, Xiaoyan</creatorcontrib><creatorcontrib>Wu, Tong</creatorcontrib><creatorcontrib>Hu, Kai</creatorcontrib><title>Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp90E1OwzAQBWALgUQpHICdL2CwncRpxaoECkiVQG0llpFjj1WjpA62A8qJuCbpzxKxmsXovRl9CF0zesPYhN9WtXOacMo5YSJNU3GCRizjE0Ipp6doRCkVJJ3m7BxdhPBBKUsTno3Qz6qrAnx2sI14BcpttfQ9LmZLssYF1DVeb8DLtsfvMuBV14K3zuPocLGBxsXj0m7xm4x2KAn428YNXoLxUkXn-9sl1LINoPE92Rcu-qbduEZiaSJ4PJe27jxgZ_BsGy0pHtj0j_uX6MzIOsDVcY7Rev64Lp7J4vXppZgtiGJJLggwzYBPMzkxFXDIjZ4ynacakmwwUVViklyC4jwTE6VSoxkHrgQokVZCJ8kYsUOt8i4ED6ZsvW0GkpLRcgdd7qHLHXR5gB4yd4cMDH99WfBlUAOFAm09qFhqZ_9J_wKBFIgj</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Yang, Fan</creator><creator>Liu, Rui</creator><creator>Xu, Teng</creator><creator>Zheng, Peihao</creator><creator>Feng, Shaomei</creator><creator>Guo, Yuelu</creator><creator>Ma, Lixia</creator><creator>SHI, Hui</creator><creator>Deng, Biping</creator><creator>Ke, Xiaoyan</creator><creator>Wu, Tong</creator><creator>Hu, Kai</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy</title><author>Yang, Fan ; Liu, Rui ; Xu, Teng ; Zheng, Peihao ; Feng, Shaomei ; Guo, Yuelu ; Ma, Lixia ; SHI, Hui ; Deng, Biping ; Ke, Xiaoyan ; Wu, Tong ; Hu, Kai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1376-e1d1e295a8fbe2e7fd91d74de35446cb3f37aec22568cc4fd12e2c6ec64b6d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Fan</creatorcontrib><creatorcontrib>Liu, Rui</creatorcontrib><creatorcontrib>Xu, Teng</creatorcontrib><creatorcontrib>Zheng, Peihao</creatorcontrib><creatorcontrib>Feng, Shaomei</creatorcontrib><creatorcontrib>Guo, Yuelu</creatorcontrib><creatorcontrib>Ma, Lixia</creatorcontrib><creatorcontrib>SHI, Hui</creatorcontrib><creatorcontrib>Deng, Biping</creatorcontrib><creatorcontrib>Ke, Xiaoyan</creatorcontrib><creatorcontrib>Wu, Tong</creatorcontrib><creatorcontrib>Hu, Kai</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Fan</au><au>Liu, Rui</au><au>Xu, Teng</au><au>Zheng, Peihao</au><au>Feng, Shaomei</au><au>Guo, Yuelu</au><au>Ma, Lixia</au><au>SHI, Hui</au><au>Deng, Biping</au><au>Ke, Xiaoyan</au><au>Wu, Tong</au><au>Hu, Kai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>10384</spage><epage>10385</epage><pages>10384-10385</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-164446</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0006-4971
ispartof	Blood, 2022-11, Vol.140 (Supplement 1), p.10384-10385
issn	0006-4971 1528-0020
language	eng
recordid	cdi_crossref_primary_10_1182_blood_2022_164446
source	EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title	Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A30%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subsequent%20Secondary%20CAR-T%20Cell%20Therapy%20Was%20Superior%20to%20Chemotherapy%20in%20Patients%20with%20Refractory/Relapsed%20B-Cell%20Lymphoma%20after%20Failure%20of%20Anti-CD19%20CAR-T%20Cell%20Therapy&rft.jtitle=Blood&rft.au=Yang,%20Fan&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=10384&rft.epage=10385&rft.pages=10384-10385&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-164446&rft_dat=%3Celsevier_cross%3ES000649712206222X%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S000649712206222X&rfr_iscdi=true